BEGIN:VCALENDAR
PRODID:Vermont Department of Health
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0500
END:STANDARD
END:VTIMEZONE
VERSION:2.0
BEGIN:VEVENT
UID:168cceb1-9fe2-4fb9-8441-1c99a5a5f1cb
SUMMARY:Outreach-Based Long-Acting Injectable Buprenorphine
DTSTAMP:20261121T090900Z
DTSTART;TZID=America/New_York:20260121T150000
DTEND;TZID=America/New_York:20260121T160000
DESCRIPTION:Outreach-Based Long-Acting Injectable Buprenorphine: A Viable Pathway to Closing OUD Treatment GapsOverdose deaths involving fentanyl increased by 45% from 2021 to 2022 in Washington State, disproportionately involving people experiencing houselessness, highlighting the urgent need to increase access to medications for opioid use disorder (MOUD) in this population. A multidisciplinary outreach team is successfully breaking down those barriers by offering field-based long-acting injectable buprenorphine (LAI-BUP) to people with opioid use disorder in outreach settings including permanent support housing sites. Field-based LAI-BUP injections offer a significant advantage to this population, providing a reliable and convenient long-acting option that increases sustained therapeutic OUD treatment and ultimately aiding in peoples’ continued success in housing.Learn more and registerFor trainings that indicate Continuing Education Units (CEUs) are available, contact your licensing or certif
LOCATION:Virtual
END:VEVENT
END:VCALENDAR